Seeking Alpha

crwenewswire's  Instablog

crwenewswire
Send Message
  • Oxygen Biotherapeutics Announces First Quarter FY2011 Financial Results Conference Call and Webcast 0 comments
    Sep 6, 2010 1:16 PM | about stocks: OXBT

     

    DURHAM, N.C., Sept. 3, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced that the company will report first quarter fiscal year 2011 financial results following the close of the U.S. financial markets on Thursday, September 9, 2010.

    The Company will host a conference call to discuss these results on Friday, September 10, 2010 at 2 p.m. EDT. Interested parties can access the conference live via webcast or telephone . The live webcast will be available in the investor relations section of our website at www.oxybiomed.com. A replay of the webcast will be available at the same location for a limited time. The telephone numbers to access the live conference call are (800) 776-0420 (U.S. and Canada) or (913) 312-0653 (international.) The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international) for a limited time. The access code for the call and the replay is 7491264.

    About Oxygen Biotherapeutics, Inc.

    Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The Company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte® that is being formulated for both intravenous and topical delivery for conditions including but not limited to traumatic brain injury, decompression sickness and topical wounds. This same PFC is included in the Company's full line of DERMACYTE personal skin care products. More information is available at www.oxybiomed.com or www.buydermacyte.com.

    The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277

    Caution Regarding Forward-Looking Statements

    This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include the expansion of development of the Oxycyte and DERMACYTE product lines and the timing of the introduction of those new products. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current reports on Form 10-Q and Form-10K. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    CONTACT: Oxygen Biotherapeutics, Inc.
    Ellen Corliss, Vice President, Corporate Communications
    & Investor Relations
    (919) 806-4405

    ********************************************************************

    The Views and Opinions Expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.

    THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

    Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more athttp://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCQB:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCQB:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCQB:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCQB:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCQB:CRWE), if paid in stock, can and may sell those securities during the advertising period

Back To crwenewswire's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.